Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 55 articles:
HTML format
Text format



Single Articles


    December 2018
  1. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    PubMed     Text format     Abstract available


    October 2018
  2. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    PubMed     Text format     Abstract available


  3. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    PubMed     Text format     Abstract available


  4. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Text format     Abstract available


  5. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Text format     Abstract available


    August 2018
  6. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    PubMed     Text format     Abstract available


    July 2018
  7. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    PubMed     Text format     Abstract available


  8. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    PubMed     Text format     Abstract available


  9. HILLIARD C
    Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
    PubMed     Text format    


  10. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
    Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
    PubMed     Text format    


    June 2018
  11. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    PubMed     Text format     Abstract available


  12. SHI T, Jiang R, Yu J, Yang H, et al
    Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
    PubMed     Text format     Abstract available


    March 2018
  13. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
    Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
    PubMed     Text format     Abstract available


    January 2018
  14. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
    Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  15. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  16. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available


  17. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    August 2017
  18. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  19. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    PubMed     Text format     Abstract available


  20. MINLIKEEVA AN, Freudenheim JL, Cannioto RA, Eng KH, et al
    History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  21. CHEN Y, Wang DD, Wu YP, Su D, et al
    MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Text format     Abstract available


  23. TABUNG FK, Huang T, Giovannucci EL, Smith-Warner SA, et al
    The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  24. MENON U, McGuire AJ, Raikou M, Ryan A, et al
    The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  25. ITAMOCHI H, Oishi T, Oumi N, Takeuchi S, et al
    Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  26. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  27. SERENI MI, Baldelli E, Gambara G, Ravaggi A, et al
    Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  28. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available


  29. BANDERA EV, Lee VS, Qin B, Rodriguez-Rodriguez L, et al
    Impact of body mass index on ovarian cancer survival varies by stage.
    Br J Cancer. 2017 Jun 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  30. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Text format     Abstract available


    May 2017
  31. PLAYDON MC, Nagle CM, Ibiebele TI, Ferrucci LM, et al
    Pre-diagnosis diet and survival after a diagnosis of ovarian cancer.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  32. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  33. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  34. DIXON SC, Nagle CM, Wentzensen N, Trabert B, et al
    Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  35. PHELPS DL, Borley JV, Flower KJ, Dina R, et al
    Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  36. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  37. FALLOWFIELD L, Solis-Trapala I, Menon U, Langridge C, et al
    The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  38. SHATHASIVAM P, Kollara A, Spybey T, Park S, et al
    VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  39. KIM SJ, Rosen B, Fan I, Ivanova A, et al
    Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  40. LINDEMANN K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, et al
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
    Br J Cancer. 2017 Jan 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  41. KAR SP, Adler E, Tyrer J, Hazelett D, et al
    Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  42. HEUDEL PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, et al
    Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  43. KOMMOSS S, Kommoss F, Diebold J, Lax S, et al
    Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  44. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  45. LICAJ I, Jacobsen BK, Selmer RM, Maskarinec G, et al
    Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  46. LI X, Chen W, Zeng W, Wan C, et al
    microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  47. LEDERMANN JA, Harter P, Gourley C, Friedlander M, et al
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  48. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  49. KONECNY GE, Kristeleit RS
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  50. SHAFRIR AL, Babic A, Tamimi RM, Rosner BA, et al
    Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  51. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  52. DONAT-VARGAS C, Akesson A, Berglund M, Glynn A, et al
    Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  53. QIN B, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al
    Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  54. KOMMOSS S, Gilks CB, du Bois A, Kommoss F, et al
    Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  55. VAN DER PUTTEN LJ, Visser NC, van de Vijver K, Santacana M, et al
    L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    Br J Cancer. 2016 Aug 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: